API | anifrolumab

anifrolumab (Saphnelo) Report issue

Biologics mAb Approved ^FDA First in Class Fast Track ^FDA

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
anifrolumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Interferon alpha/beta receptor 1 (Homo sapiens) ^UniProt
- Interferon alpha/beta receptor 1 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

anifrolumab | medi-546

Organizations (16)

Research & Development (16)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (1)

Lupus Erythematosus, Systemic (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Arthritis, Rheumatoid (Phase 2)

Atherosclerosis (Phase 1)

Cardiovascular Diseases (Phase 1)

Healthy Volunteers (Phase 1)

Lupus Erythematosus, Cutaneous (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Lupus Nephritis (Phase 3)

Pharmacokinetics (Phase 1)

Safety (Phase 1)

Scleroderma, Systemic (Phase 3)

Sjogren's Syndrome (Phase 2)

Vitiligo (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 24
# of Trial Organizations: 16

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue